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There are 67 proteins in the human mitochondrial transport protein family. They have been identified from among the proteins of the RefSeq
database on the basis of sequence similarity to proteins that have been functionally identified as mitochondrial transport proteins. They have also
been identified by matching their predicted structure to the high resolution structure of the bovine ADP/ATP T1 transporter subunit/
carboxyatractyloside complex. 74 nonsynonymous single nucleotide polymorphisms (nsSNP) have been identified in their gene sequences. These
nsSNPs are present in genes of 30 of the proteins. No nsSNP has been found in 24 of the protein genes and no search has as yet been carried out
on the rest (13) of them. The largest number of nsSNPs are in the ADP/ATP T3 transporter, the uncoupling protein 3 L, and the phosphate
transporter genes with 7, 6, and 6, respectively. nsSNPs are located in groups along the protein sequence suggesting that certain protein domains
are too critical for transport function to tolerate mutations. This interpretation has been validated with mutation and function studies of the
phosphate transporter. Human diseases have been identified with replacement mutations in seven of these proteins. Their genes are not
abnormally susceptible to mutations since they have the smallest number of nsSNPs. Disease causing mutations have also been observed as:
substitution, silent (may affect stability of messages), frameshift (protein truncation or elongation), splicing (exon skipping), residue deletion.
Disease causing mutations have only been identified in few transporter genes because others do not yield dramatic symptoms or are essential and
thus lethal. Mutations in other transporter genes may also only have a major impact through their combination with other genes and their
nsSNPs.
© 2006 Elsevier B.V. All rights reserved.Keywords: Human; Mitochondria; Transport; Protein; Carrier1. Introduction
Cytosolic metabolic pathways often carry out several of their
essential reactions within the mitochondrial matrix. This
requires that charged metabolites must cross the mitochondrial
inner membrane. Transfer of charged metabolites across this
membrane in an uncontrolled manner will be deleterious to the
membrane potential that is essential for oxidative phosphory-
lation. A cell that becomes deficient in ATP is almost certain to
suffer cell death. The mitochondrial transport proteins have the⁎ Tel.: +1 617 658 7775; fax: +1 617 972 1753.
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doi:10.1016/j.bbabio.2006.05.024essential role of transporting charged metabolites in a highly
controlled manner across the mitochondrial membrane while
retaining the membrane potential that is essential for oxidative
phosphorylation. At the same time the transporters also have to
insure that metabolites are transported across the mitochondrial
membrane at a rate sufficient to satisfy the needs of the
metabolic pathways.
With the availability of the human genome and extensive
analyses that have already been carried out, it has become clear that
there are over 65 transport proteins in human mitochondria [1].
Additional proteins that do not belong to this transporter family
transport metabolites and other substances across the mitochon-
drial membrane [2,3]. This communication concerns itself only
with transport proteins that belong to the human mitochondrial
Table 1
The human mitochondrial transport/carrier proteins. Nonsynchronous SNPs and disease causing mutations
SF a NCBI accession number
(SLC25 ID) b
Function/Name c (rs d) cr/nsSNP e location f Human disease causing
mutations
Ref. g
1 NP_005975.1 (A1) citrate (311) No nsSNP [10, 11]
2 NP_055067.1 (A15) ornithine (301) I254L A15E, G27E, G27R [12–14]
h56 H1 H1 H1
E180K, G190D, R275Q
H4 H4 H6
truncations, rs deletion,
exon skipping
2 NP_114153.1 (A2) ornithine (301) G159C, V181G, V226I
h34 H4 H5
3 NP_005879.1
(A3 iso a precursor)
phosphate (362) no SNP map
3 NP_002626 phosphate (361) P36S, R42G, V82L,
NP_998776.1 NT NT H1
(A3 iso b precursor) W122L, V310A, V335M
H2 H6 H6
4 NP_001142.2 (A4) ADP/ATP T1 (298) no nsSNP A90D, L98P, D104G [15–19]
H2 H2 LC1
A114P, A123D, V289M
H3 H3 H6
4 NP_001143.1 (A5) ADP/ATP T2 (298) L111R, V162G, K166E
H3 h34 h34
4 NP_001627.1 (A6) ADP/ATP T3 (298) V26M, A47T, Q50R,
H1 LM1 LM1
V67L, F113L, S242F,
H2 H3 LM3
G283W
H6
4 NP_112581.1 (A31) ADP/ATP (315) no nsSNP
5 NP_068605.1 (A7) UCP1 (307) M229L R40W, A64T, V137M [20–22]
H5 H1 h12 H3
K257N
h56
5 NP_003346.2 (A8) UCP2 (309) A55V, R96C
LC1 H2
[23–25]
5 NP_003347.1 (A9) UCP3 L (312) V9M, T52M, R70W, G84S
H2
truncation, exon deletion
[26–28]
NT LM1 h12
V102I, R119Q, R282C
H2 H3 H6
5 NP_073714.1 (A9) UCP3 S (275) no SNP map
6 NP_036272.2 (A10) dicarboxylate (287) L188R
H4
[29]
7 NP_003553.2 (A11) oxoglutarate (314) no nsSNP
8 NP_003696.2 (A12) aralar 1 (678) no nsSNP [30]
8 NP_055066.1 (A13) citrin, aralar 2 (675) S83Y, E141K, L232I, E601K [31–34]
NT NT NT H6
V507L
H4
truncation, splicing mutation
9 NP_003942.1 (A14) UCP5 L BMCP1 (325) A19T, E55A
NT H1
[35]
9 NP_073721.1 (A14) UCP5 S BMCP1 (322) no SNP map [35]
9 NP_001010875.1 (A30) UCP5 KMCP1 (291) no nsSNP
10 NP_689920.1 (A16) CoA Grave's disease
autoantigen (332)
no nsSNP
11 NP_006349.1 (A17) ADP/ATP (peroxisomal) (307) H98R, L230M
LC1 H5
12 NP_078974.1 (A22) glutamate 1 (323) E161?, P166S
LM2 LM2
12 NP_113669.1 (A18) glutamate 2 (315) no nsSNP
13 NP_068380.2 (A19) deoxynucleotide (320) no nsSNP G177A
H4
[36]
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Table 1 (continued)
SF a NCBI accession number
(SLC25 ID) b
Function/Name c (rs d) cr/nsSNP e location f Human disease causing
mutations
Ref. g
14 NP_000378.1 (A20) carnitine/acylcarnitine (301) Q238R G28C, D32N, G54WT55A, [37–41]
H5 H1 H1 LM1 LM1
R133W, R178Q, P230R,
H3 H4 H6
D231H, Q238R, A281V
H5 H5 H6
truncation, exon skipping,
rs deletion, CT extension
14 NP_997000.2 UCP liver specific (308) no nsSNP
15 NP_085134.1 (A21) oxodicarboxylate (299) W299C
CT
16 NP_077008.2 (A23) APC2, SCaMC-3 (468) no nsSNP
16 NP_037518.2 (A24 iso 1) SCaMC-1 (476) no nsSNP
16 NP_998816.1 (A24 iso 2) APC1 (458) no SNP map
16 NP_443133.2 (A25 iso a) SCaMC-2a (469) no nsSNP
16 NP_001006642.1 (A25 iso b) SCaMC-2b (503) no SNP map
16 NP_001006643.1 (A25 iso c) SCaMC-2c, APC3 (489) no SNP map
16 NP_001006644.1 (A25 iso d) SCaMC-2d (366) no SNP map
16 NP_775908.1 LOC284427 MGC34725 (232) T120S
H4
17 NP_001009937.1 (A26 iso a) AdoMet (274) no SNP map
17 NP_775742.2 (A26 iso b) AdoMet (186) T120M
H3
17 NP_001009938.1 (A26 iso c) AdoMet (66) no SNP map
18 AAD16995.1 (A27) UCP4 (323) no SNP map
18 NP_004268.2 (A27) UCP4 (134) no nsSNP
19 AAH76399.1 (A28) MRS3/4 metal transport (364) no SNP map
19 NP_112489.2 (A28) MRS3/4 metal transport (177) no nsSNP
19 NP_057696.1 (A37) (338) no nsSNP
19 NP_061049.2 (A37 iso 2) (155) no SNP map
20 NP_689546.1 (A29 iso a) carnitine/acylcarnitine (237) no nsSNP
20 NP_001034444 (A29 iso b) carnitine/acylcarnitine (303) no SNP map
21 NP_110407.2 (A32) folate (315) R117H
LC1
22 NP_060345.1 LOC54977 FLJ20551 (304) no nsSNP
23 NP_660348.1 LOC203427(341) L334P
CT
24 NP_055470.1 LOC9673 KIAA0446 (314) S52I
LM1
25 NP_660325.1 LOC153328 (157) G40R
LM2
26 NP_057100.1 LOC51629 (351) V186G, Q201R, F239L
LM2 h34 LC2
S246F, A322V
LC2 H6
27 NP_997231.1 (A34) CAH70849 (304) no nsSNP
27 NP_958928.1 (A35) (295) no nsSNP
28 NP_115691.1 MGC4399 (321) no nsSNP
28 NP_060625.1 (A36) (310) no nsSNP
29 NP_061331.2 MCFP (338) T123I, L162V, K186Q
H2 H3 h34
30 NP_872362.1 LOC283130 (335) L284F CT
31 NP_848621.1 MGC26694 S26?, S39P, W132R,
XP_209204 LOC284439 (318) NT H1 H3
L312M
CT
32 NP_001029344 MCART2 (297) L249I
H5
32 NP_219480.1 MCART1 (297) no nsSNP
33 NP_001012773 MCART6 (307) R262W, R264Q
XP_377034 h56 H6
(continued on next page)
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Table 1 (continued)
SF a NCBI accession number
(SLC25 ID) b
Function/Name c (rs d) cr/nsSNP e location f Human disease causing
mutations
Ref. g
34 NP_620128.1 LOC91137 (418) no nsSNP
35 XP_372410.2 LOC390192 (298) A21T, A125G, K197R,
H1 H3 H5
R263H
H6
36 NP_055156.1 MTCH1 (372) P98A, F149L, P214R
H1 H2 H3
37 NP_055157.1 MTCH2 (303) D3V, D3G, P290A [42]
H1 H1 H6
a SF is subfamily, i.e. members have at least one transmembrane helix sequence (H1, H3, or H5, e.g. see Fig. 1 and Ref. [1]) with similarity E-value of less than 1e−03.
b NCBI is the National Center for Biotechnology Information with detailed information on the protein/gene under the accession number (http://www.ncbi.nlm.nih.
gov/RefSeq/). SLC25 is their designation for this transporter family with A1 to A37 being the identification (ID) numbers of those members of this transporter family
that are part of their official family. Iso a or iso b refer to isoforms of the transporters.
c Label refers to transported substrate if it has been identified, a common name or database designation depending on what is available. ADP/ATP T3 (adenine
nucleotide exchange, T3 isoform), UCP (uncoupling protein), aralar (Ca++-stimulated aspartate–glutamate transporter), citrin (Ca++-binding aspartate–glutamate
carrier), BCMP (mitochondrial carrier protein in neurons), KMCP (kidney mitochondrial carrier protein), APC (ATP–Mg/Pi carrier), SCaMC (short Ca++-dependent
mitochondrial carrier), AdoMet (S-adenosylmethionine), MRS (mitochondrial RNA splicing).
d rs is number of amino acid residues in the protein.
e cr (amino acid of contig reference sequence followed by its location counted from the N-terminal), ns (nonsynonymous substitution is when the allele has a new
codon at that location that encodes a different amino acid), SNP (single nucleotide polymorphism, for such a nucleotide sequence variation to be considered a SNP it
must occur in at least 1% of the population) (http://www.ncbi.nlm.nih.gov/SNP).
f Location (mutation sites were projected onto human PTP (NP_002626 or SLC25 A3 iso b) by sequence alignments that include predicted and actual helices. NT
and CT are protein regions beyond N-terminal of H1 and C-terminal of H6. For other abbreviations see Fig. 1. (http://bioinf.cs.ucl.ac.uk/psipred/psiform.html));
location refers to protein regions as in Fig. 1.
g Many relevant references when not cited directly are cited under the NCBI accession number or in Ref. [1].
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mutations that can yield partial inhibition of transport activity.
Such partial inhibition of a single transporter or in combination
with partial inhibitions of other transport protein activities can
significantly impact cellular metabolism.
This communication identifies replacement mutations due
to the nonsynonymous SNPs of the human mitochondrial
transport proteins (http://www.ncbi.nlm.nih.gov/SNP/). Also
identified have been the mutations in the human transport
proteins that have been shown to cause human diseases. These
data have been combined with the extensive research results
on mutations of the mitochondrial phosphate transport pro-
tein [5] to identify patterns of inhibitory and non-inhibitory
mutations that may be common to all mitochondrial transport
proteins.
2. Results and discussions
Table 1 shows the human mitochondrial transport proteins
as they have been identified from the RefSeq database (http://
www.ncbi.nlm.nih.gov/genome/guide/human/). This total
number of proteins changes somewhat as it becomes clearer
which proteins are expressed, which have been incorrectly
predicted, and which have been published with minor
differences that proved to be incorrect. Some of the proteins
are partial sequences of others. Nevertheless their existence is
highly probable since their sequences were obtained from cDNA
libraries. It is important to characterize the functions of such
partial sequences.
The data in Table 1 also show replacement mutations due to
single nucleotide polymorphisms (SNPs) in the transport proteingenes.Much effort is currently being placed into the identification
of gene pools based on single nucleotide differences between
genes of individuals. The expectation is that correlations can be
made between certain gene pools and common diseases such as
cancer, stroke, heart disease, diabetes, depression, and asthma
which in most cases have not been successfully identified with a
mutation in a single gene. These efforts should also lead to a
tailoring of individual doses of pharmaceuticals to individuals and
to a minimizing of side effects due to pharmaceuticals.
In Table 1 are shown only the nonsynonymous SNP (nsSNP)
since they are more relevant to protein function. Synonymous
SNPs may have a role in the amount of protein that is expressed
in the cell by having an effect on the stability of the message.
The nsSNPs are likely random mutations and it is of interest to
map those of all members of this transport protein family onto a
single transport protein of this family to determine whether the
nsSNPs form clusters and whether these clusters are in regions
of the protein that are less sensitive to mutations. The human
mitochondrial phosphate transport protein (PTP) was chosen.
The yeast mitochondrial phosphate transport protein with the
same physiological role has been extensively characterized with
single site mutations and function-relevant regions of the pro-
tein have been identified [5].
Fig. 1 shows the nsSNPs of the members of the mitochondrial
transport protein family as projected onto the human mitochon-
drial phosphate transporter (NP_002626 in Table 1). These pro-
jections were obtained in the following manner. The sequence of
each protein of Table 1 was compared to the protein structures in
the protein data bank (PDB) by using the mGenThreader pro-
gram (http://bioinf.cs.ucl.ac.uk/psipred/psiform.html). All pro-
teins in Table 1 showed the best fit with the structure of the
Fig. 1. Replacement mutations due to nsSNPs of the human mitochondrial transport proteins projected (see text) onto the topological diagram of the human
mitochondrial phosphate transport protein (PTP) (NP_002626). The red circled residues identify locations of these replacement mutations. The number within each
circle indicates the number of mutations at that location. Locations with more than one of these mutations show a red circle with a proportionally heavier
circumference. The helices are indicated (H1 to H6) and so are the three short matrix-side helices (h12, h34, h56). Also the matrix loops (LM1, LM2, LM3) and the
cytosolic loops (LC1, LC2) are indicated.
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complex [6]. The program also yields an alignment of the two
protein sequences, e.g., human sample sequence with a mutation
and bovine ADP/ATP T1 transporter sequence, taking account of
predicted and actual helices. Such an alignment was used to
identify the residue in the bovine ADP/ATP T1 transporter sub-
unit similar to the nsSNP-related amino acid of the human sample
sequence. Then the same protein sequence alignment betweenFig. 2. Human disease causing replacement mutations (solid red) of the human mitoch
inhibit phosphate transport activity (blue circles) of the yeast mitochondrial PTP arethe human mitochondrial phosphate transporter and the bovine
ADP/ATP T1 transporter made the assignment of the nsSNP-
related amino acid of the sample sequence in the human phos-
phate transporter possible.
Fig. 1 shows that the nsSNP-related mutations fall into groups
or clusters. Even more interesting is that they are absent from
certain regions of the protein. Thus along helix 1 (H1) there are
some regions without mutations. There are none near Cys26ondrial transport proteins and replacement mutations that completely or severely
projected onto the topological map of the human mitochondrial PTP.
Fig. 3. Replacement mutations due to the nsSNPs of the human mitochondrial transport proteins (red circles, see Fig. 1) and replacement mutations of the human
mitochondrial transport proteins that cause human diseases (solid blue, Fig. 2) have been projected onto the topological map of the human mitochondrial PTP.
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of the homodimeric PTP [7] and thus of key mechanistic impor-
tance. The region near the C-terminal of this helix 1 has also been
shown with site-directed mutagenesis and inhibitor binding stud-
ies to be critically important for the function of PTP. Again, there
are nomutations in this region. The region aroundHis30 is critical
but unique only to the phosphate transporter (PTP). It has been
suggested to be part of the mechanism that links proton transport
to phosphate transport within PTP [8]. This seems to be not
critical to some of the other transporters since nsSNPs are located
in this region and especially at the His30 site. Short helix h12 is
also of interest since it has been demonstrated to be at or near the
intersubunit site of the bovine ADP/ATP transporter, i.e., this has
been demonstrated by the formation of a transport-inhibiting
disulfide in only the m-state or the no-inhibitor-state of the trans-
porter [9]. Thus this region of the transporters of this family must
also be critical to the transport process in general and thus most
sensitive to mutations. Helices 2, 3, 4 and 5 also have patches of
12 to 15 residues without mutation. This seems to be less so for
helix 6. Of interest is also that the C-terminal amino acids of the
protein (C-terminal of helix 6 to C-terminal of the protein) are
without mutations. However there could be reasons for that, i.e.,
other proteins have shorter C-terminal sequence beyond helix 6
and have no amino acids/mutations to be projected onto the C-
terminal amino acids of PTP.
It should also be noted that nothing is known about the human
individuals from whom these DNA samples were obtained. Thus
it is not known for most of these transport proteins which muta-
tions affect their function in a deleterious manner, i.e., what kind
of substitutions are tolerated at which locations. It appears how-
ever as if there are regions that aremechanistically important to all
of these transport proteins as discussed earlier.
Fig. 2 shows replacement mutations that have been identified
as causing human diseases (Table 1). Also in Fig. 2 are shownthe locations of replacement mutations that severely or totally
inhibit phosphate transport [5]. A most obvious difference be-
tween Figs. 1 and 2 is that the collection of disease causing
human mutations fall into the C-terminal regions of helices 1, 3,
and 5where substitution have themost dramatic effect on transport
activities in all the transporters that have been characterized. It
should also be noted that there are three mutations in short helix
h12 which showed no nsSNP-related mutation in Fig. 1. It is also
quite significant that while five amino acids of helix 2 and near the
N-terminal of helix 2 are located along the same surface of the
helix, each blocking transport severely upon replacement (Fig. 2
andRef. [5]), four amino acids that upon replacement cause human
diseases are similarly located along one side of helix 6 (Fig. 2). Of
interest is also that almost all amino acids that upon replacement
yield human diseases are located within helices (Fig. 2).
Fig. 3 shows a combination of both the nsSNP-related muta-
tions and the disease-causing mutations. There is little overlap
between their locations. However they do complement each other
by often being located on the same side of a helix surface. None of
the mutations that cause truncation or elongation of proteins
(frame shifts or exon skipping) are listed in Table 1. Often proteins
with suchmutations in their genes have a very short half life in the
membrane and become often undetectable.
It will be interesting to determine whether SNP-related mu-
tations of mitochondrial proteins in general or the transporters
specifically will permit the identification of individuals with a
higher susceptibility towards some diseases and with smaller or
larger side effects from some pharmaceuticals.3. Note added in proof
Mutation (Pro206Leu) (F. Molinari, A. Raas-Rothschild, M.
Rio, G. Fiermonte, F. Encha-Razavi, L. Palmieri, F. Palmieri, Z.
1269H. Wohlrab / Biochimica et Biophysica Acta 1757 (2006) 1263–1270Ben-Neriah, N. Kadhom, M. Vekemans, T. Attie-Bitach, A.
Munnich, P. Rustin, L. Colleaux, Impaired mitochondrial
glutamate transport in autosomal recessive neonatal myoclonic
epilepsy, Am. J. Hum. Genet. 76 (2005) 334-339.) in human
glutamate 1 (NP_078974.1, SLC25A22) is located at Ala186 in
Figure 2 (solid red, H4) and Figure 3 (solid blue, H4).
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